Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03079999 · ClinicalTrials.gov registry record · Phase 2
Study of Aspirin in Patients With Vestibular Schwannoma
A Phase 2 study of Vestibular Schwannoma and Neurofibromatosis 2, sponsored by Massachusetts Eye and Ear Infirmary.
- Active
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
- 5
- Study locations
NCT03079999: Active Phase 2 study of Vestibular Schwannoma and Neurofibromatosis 2, sponsored by Massachusetts Eye and Ear Infirmary.
NCT03079999 is a Phase 2 study of Vestibular Schwannoma and Neurofibromatosis 2 that is active but no longer recruiting, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 97 participants, above the 39-participant average among 7 other Vestibular Schwannoma trials with a reported enrollment target (149% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03079999, a Phase 2 study of Vestibular Schwannoma and Neurofibromatosis 2, is active but no longer recruiting, sponsored by Massachusetts Eye and Ear Infirmary.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.
Primary Outcome
Progression Free Survival (PFS) is the length of time from start of study treatment to tumor growth of more than 20%.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aspirin
Study Locations (5)
California
- Stanford Otolaryngology/HNS - Stanford
Florida
- University of Miami - Miami
Massachusetts
- Massachusetts Eye and Ear - Boston
Minnesota
- Mayo Clinic - Rochester
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2018-06-11 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
What the registry record for NCT03079999 still lists
NCT03079999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, above the 39-participant average among 7 other Vestibular Schwannoma trials with a reported enrollment target (149% higher).
The record links to 3 conditions, with Vestibular Schwannoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03079999 lists 5 locations in 5 states (California, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT03079999 about?
NCT03079999 is a clinical study titled "Study of Aspirin in Patients With Vestibular Schwannoma". This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.
What is the current status of trial NCT03079999?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2018-06-11. Estimated completion is 2029-02.
What conditions does trial NCT03079999 study?
This clinical trial studies the following conditions: Vestibular Schwannoma, Neurofibromatosis 2, Acoustic Neuroma.
What interventions are being tested in trial NCT03079999?
The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG).
Who is sponsoring clinical trial NCT03079999?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03079999 being conducted?
This trial has 5 study locations across California, Florida, Massachusetts, Minnesota, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vestibular Schwannoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
ACTIVE NOT RECRUITING · Phase 2
-
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
ACTIVE NOT RECRUITING · Phase 2
-
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
COMPLETED · Phase 2
-
StableEyes With Active Neurofeedback
RECRUITING · NA
-
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
RECRUITING · Phase 1
-
CI Following VS Removal or Labyrinthectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI